Transdermal CBD Gel Safety in Fragile X: Clinical Data
Comments Off on Transdermal CBD Gel Safety in Fragile X: Clinical Data
April 15, 2026
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) is being studied long-term in children and adolescents with Fragile X syndrome, targeting behavioral symptoms linked to dysregulated endocannabinoid signaling. Interim data from this open-label…
Safety of cannabidiol versus placebo in healthy population: a systematic review and meta-analysis.
Comments Off on Safety of cannabidiol versus placebo in healthy population: a systematic review and meta-analysis.
March 20, 2026
Cannabidiol (CBD) has gained significant attention for its potential therapeutic benefits, but its safety profile in healthy populations remains underexplore...
Using measured cannabidiol and tetrahydrocannabinol metabolites in urine to differentiate marijuana use from consumption of commercial cannabidiol products
Comments Off on Using measured cannabidiol and tetrahydrocannabinol metabolites in urine to differentiate marijuana use from consumption of commercial cannabidiol products
December 7, 2021
The current method for detection of marijuana use measures 11-nor-carboxy-Δ9-tetrahydrocannabinol (11-COOH-THC), the major metabolite of THC in a person’s urine. However, commercially available CBD products sold without purity regulations often contain…